Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

788.19 -1.13 (-0.14%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
7 High Priced Stocks That Would Benefit From a Stock Split
These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names. 
Via InvestorPlace
Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today
Via Benzinga
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation. 
Via The Motley Fool
The 3 Best Healthcare Stocks to Buy in July 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy. 
Via InvestorPlace
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Eli Lilly is a good stock to buy, but these should be even better. 
Via The Motley Fool
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
The study comes out of a Harvard teaching hospital based in Boston. 
Via Investor's Business Daily
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce... 
Via Benzinga
Exposures Product Safety
'Other Bets' Startup Mineral Bites The Dust In Google Cost Cutting Move
Alphabet said it's shuttering agricultural startup Mineral, one of its "Other Bets" ventures, in a cost-cutting move for Google stock. 
Via Investor's Business Daily
Top 3 Health Care Stocks That May Crash This Quarter
Via Benzinga
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
Exposures Product Safety
These 4 Vanguard ETFs Soared Over 20% in the First Half of 2024. Here's Which One Is Most Likely to Fly Even Higher.
These Vanguard ETFs have a lot in common. 
Via The Motley Fool
Topics ETFs
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
The treatment is intended for adults in the early symptomatic stages of Alzheimer's disease. 
Via Benzinga
Exposures Product Safety
Eli Lilly Receives FDA Approval For Its Alzheimer’s Drug Kinsula
Eli Lilly & Co received approval for its Alzheimer’s drug from the Food & Drug Administration on Tuesday. The development is significant as it expands treatment options for the neurological disorder... 
Via Talk Markets
Exposures Product Safety
Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory. 
Via Benzinga
Topics Stocks
Exposures US Equities
AMZN Stock Outlook: Amazon’s Next Growth Wave Could Make Early Investors Rich
After effectively eliminating a threat from low-cost Chinese e-commerce websites and Amazon stock remains attractive. 
Via InvestorPlace
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
The company is on deck to rival Biogen and Eisai's Leqembi. 
Via Investor's Business Daily
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
We also talk about weight loss drugs and sleep apnea, and other stock market news. 
Via The Motley Fool
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
American leaders push for lower drug prices, highlighting recent legislation and widespread support for affordable medications. The Inflation Reduction Act caps insulin costs and Medicare now... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
The duo make weight-loss and diabetes drugs that sell for more than $1,000 a month before insurance kicks in. 
Via Investor's Business Daily
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly... 
Via Benzinga
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
Eli Lilly Soars To 52-Week High: Can The Momentum Continue?
Eli Lilly is up a remarkable 97.38% over the past year and 55.32% year-to-date. Strong technical indicators suggest continued momentum. 
Via Benzinga
Is Google Stock A Buy With Earnings Due, New CFO Waiting In The Wings?
Up big in 2024 on AI buzz, Google reports earnings in July with a new CFO set to take over. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nvidia Among Biggest Stock Market Winners In 2024, But This Is No. 1
Several AI stocks among the S&P 500's best performers. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.
These stalwart companies could help you safely grow your wealth. 
Via The Motley Fool
2 Top Healthcare Stocks to Buy in June
Healthcare businesses tend to hold up through various economic cycles. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.